Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388629 | 0.89 | HRH3 (0.64) | HRH3CTSKMAPT | |
| SCHEMBL4393985 | 0.88 | HRH3 (0.50) | HRH3SMN1; SMN2KEAP1CTSKKDM4E | |
| SCHEMBL4392329 | 0.85 | HRH3 (0.50) | HRH3SMN1; SMN2KEAP1CTSKKDM4E | |
| SCHEMBL4383770 | 0.85 | HRH3 (0.47) | HRH3CTSKCYP1A2CYP2D6 | |
| SCHEMBL4387729 | 0.83 | HRH3 (0.44) | HRH3SMN1; SMN2KDM4EMAPTCYP1A2 | |
| SCHEMBL4383979 | 0.79 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1KDM4EMAPT | |
| SCHEMBL4389793 | 0.78 | HRH3 (0.65) | HRH3CTSKMAPTMEN1KMT2A | |
| SCHEMBL4388554 | 0.78 | HRH3 (0.61) | HRH3SMN1; SMN2KEAP1CTSKKDM4E | |
| SCHEMBL4382171 | 0.77 | HRH3 (0.60) | HRH3CTSKMAPT | |
| SCHEMBL4384351 | 0.77 | HRH3 (0.67) | HRH3CTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | HRH3 452/4885SMN1; SMN2 3979/4885KEAP1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.